Skip to content

Observational Study of Baska Mask, a New Supraglottic Airway Device

Observational Study of Baska Mask, a New Supraglottic Airway Device

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01496859
Enrollment
30
Registered
2011-12-21
Start date
2011-08-31
Completion date
2011-12-31
Last updated
2012-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Performance and Safety of a New Supraglottic Airway Device

Keywords

Baska mask, supraglottic airway, airway management

Brief summary

The Baska mask is a new supraglottic airway device . The investigators would like to assess its performance in setting in which the current standard - LMA device - is being used.

Detailed description

Our group has performed a number of studies on novel airway devices. In this study we would like to evaluate a new supraglottic airway named Baska mask. We would like to monitor certain parameters (time to and ease of insertion, failure rate, seal pressures, complications etc) as regarding the performance and safety profile of this device. This is a descriptive case series of patients undergoing airway management under general anaesthesia.

Interventions

use of a supraglottic airway device as a standard part of a general anaesthetic

Sponsors

University College Hospital Galway
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Written informed Consent * No relevant drug allergies * Body-mass index (BMI) 20-35 * Age 18-65 * Non-urgent surgery of planned duration 0-2 hrs

Exclusion criteria

* Inability of patient/parent to understand or consent for the trial * Non-English speakers * Neck pathology * Previous or anticipated problems with the upper airway or upper GI tract (reflux, hiatus hernia, oropharyngeal tumour, upper respiratory tract infection in the last 10 days etc) * BMI \>35 * Expected Difficult airway * Live Pregnancy * Increased risk for Gastric Aspiration

Design outcomes

Primary

MeasureTime frameDescription
Device Placement Success ratewithin 30 mins of anaesthesia commencement
time to placement of devicewithin 30 mins of anaesthesia commencementfrom the moment the device touched until successful ventilation achieved or device removed

Secondary

MeasureTime frameDescription
airway leak pressure of the devicewithin 30 mins of anaesthetic commencement
user-rated ease of insertion of devicewithin 30 mins of anaestesia commencement10cm visual analog score to be used
complication ratesFrom the moment general anaesthesia commenced up to 1 day postoperativelycomplications specifically monitored will be desaturation episodes, laryngospasm, blood staining of the device, lip damage. We will record other complications related to the use of the device, including but not limited to loss of airway with need to manioulate mask/switch to alternative device, regurgitation, aspiration, teeth damage.
patient comfort indicesfrom the moment the patient awake up to 1 day postoperativelyThroat pain, dysphagia and dysphonia will be assessed. 10 point verbal rating scale will be used

Countries

Ireland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026